Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 3Phase NA 2Phase 3 1Phase 1 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 44Recurrence 6Smoldering Multiple Myeloma 2Plasmacytoma 1Immunoglobulin Light-chain Amyloidosis 1Autoimmune Diseases of the Nervous System 1Anti-N-Methyl-D-Aspartate Receptor Encephalitis 1Amyloidosis 1

Interventions

Melphalan 8Dexamethasone 7Bortezomib 6Filgrastim 4Cyclophosphamide 3liposomal amphotericin B 2Early Intervention, Educational 2Darbepoetin alfa 2Clinical Protocols 2Calcium Dobesilate 2ferrous sulfate 1ferric gluconate 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1birtamimab 1auricularum 1Sucrose 1Stem Cell Transplantation 1Specimen Handling 1Pharmacogenomic Testing 1Peripheral Blood Stem Cell Transplantation 1Ondansetron 1Morphine 1Magnetic Resonance Spectroscopy 1Ketamine 1Hypericum extract LI 160 1Granulocyte Colony-Stimulating Factor 1Fentanyl 1Epoetin Alfa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Immunoglobulin Light-chain Amyloidosis × daratumumab × Clear all
NCT06022939 2026-05-06

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

SWOG Cancer Research Network

Phase 3 Recruiting
338 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡